Nuvalent, Inc.

Today, we shared positive topline pivotal results for our investigational candidate, neladalkib, in TKI pre-treated patients with advanced ALK+ NSCLC from our global ALKOVE-1 Phase 1/2 clinical trial. To us, these topline results are more than just data. They represent the courage and conviction of each one of the over 1,000 patients that has already chosen to receive neladalkib through either our ALKOVE-1 trial or our global Expanded Access Program, and the support of the broader ALK+ community. To every patient placing their trust in clinical research, thank you. You inspire us to push further every day towards our shared hope for more days living well with cancer. Learn more here: https://lnkd.in/eyubCgAn

⚡ TUNE IN ON MONDAY: Topline pivotal data for TKI pre-treated patients with advanced ALK+ NSCLC from our ALKOVE-1 clinical trial of investigational candidate neladalkib are coming. Join our live webcast & conference call on November 17, 2025 at 8:00am ET. Learn more:  https://lnkd.in/ejyAWgkE

Did you know today is #NationalBiomarkerTestingDay? Biomarker testing saves, extends, and improves lives every day. By testing for gene mutations, people living with lung cancer are exposed to more treatment options that best treat their lung cancer. Learn more ➡️ https://lnkd.in/ewDSaDW8 #LungCancerAwareness

Catch up, think big, recharge? Innovation doesn’t come from back-to-back meetings. It comes when people have the space to focus on what matters. At Nuvalent, we’re replacing the grind with #SomethingNu so our teams can do their best work. Ready to join the team? See how: https://lnkd.in/g6qZeV9S

📅 Today is National Lung Cancer Screening Day! #LungCancer isn’t just a smoker’s disease, and stories like Jim’s show that you don’t have to fit a “typical” profile to be affected. That’s why early screening and genomic testing are two important and distinct approaches to lung cancer care. Screening can catch lung cancer early when it’s most treatable, and genomic testing helps identify targeted treatments that can make a real difference. 💙 Take charge of your lung health. Talk to your doctor about screening and genomic testing today. Learn more: https://lnkd.in/gnGYjMhz #LungCancerAwarenessMonth

Meet the newest members of the #NuCrew: CT, Kristen, Brandi, James, Misty, Amy, and Kelly! 🎊 Ready, set, collaborate! 🙌

💙 This #LungCancerAwarenessMonth, we’re proud to support LUNGevity Foundation in their efforts to transform how people are diagnosed and live with #LungCancer. We look forward to celebrating the hope and progress of #LungCancerResearch at this evening’s 13th Annual Celebration of Hope and Progress in NYC, and walking in solidarity with the lung cancer community as part of the #BreatheDeepTOGETHER Walk in Somerville, MA this weekend. Together, we’re making strides towards hope and progress for every patient and family impacted by lung cancer 🌟 #BreatheDeep25

From the start of each program, we collaborate with leading physician-scientists to understand the medical needs of the patients they treat and use those insights to guide our work. This commitment to thoughtful, patient-centered innovation is part of what makes our culture #SomethingNu. Help us re-design what’s possible: https://lnkd.in/g6qZeV9S

📊 Join us at the 2025 International Association for the Study of Lung Cancer ASCO North America Conference on Lung Cancer where we'll present the first look at patient-reported outcomes from the Phase 2 portion of our ARROS-1 clinical trial of investigational candidate zidesamtinib. Learn more: https://lnkd.in/g9iV_MQH #biotech #Nuvalent

🌟 We believe that empowered teams create extraordinary work. 🌟 Our focus on advancing patient care begins with caring for our #NuCrew. That’s why we offer a supportive, flexible, and rewarding work environment designed to help our employees and their families flourish professionally, financially, and personally.